Article
13 Aug 2026
CAFC Reverses Jury Decision In Board Of Regents Of The University Of Texas System v. Boston Scientific Corp.
CONTRIBUTING SINCE MAY 2017
Oblon, McClelland, Maier & Neustadt, L.L.P
Oblon is among the largest US law firms that exclusively practice IP law. Businesses worldwide depend on Oblon to establish, protect and leverage their IP assets. Our team of 100+ legal professionals includes some of the country’s most respected practitioners. Most attorneys hold advanced degrees in engineering, physics, chemistry, biotechnology and other scientific disciplines. Oblon is headquartered within steps of the USPTO office in Alexandria, Virginia.
POPULAR TOPICS
Intellectual Property
Food, Drugs, Healthcare, Life Sciences
Oblon, McClelland, Maier & Neustadt, L.L.P are most popular:
- with readers working within the Insurance industries
COMPANY CONTENT
Article
10 Aug 2026
European Patent Office Updates Its Guidelines For Examination
Article
04 Aug 2026
USPTO Announces Relief For Those Affected By The Earthquake In Japan
Article
21 Jul 2026
IPL v. Sony: Federal Circuit Holds PTAB Did Not Violate Mandate Rule And Affirms Obviousness Determination
Article
06 Jul 2026
Final Written Decision On IPR Filed Against Patent 11,874,910 B2 "Facial Recognition Authentication System Including Path Parameters" Denied For Improper Motivation To Combine Prior Art
Article
29 Jun 2026
Patent Owner Gets Green Light For Dependent Claims Under The Recent Director Review Process
Article
21 May 2026
WEBINAR: What The Heck Is Going On In The U.S.? (Video)
Article
01 May 2026
Plural Overlapping Dimensions Found Unobvious Due To Differing Function
Article
24 Mar 2026
USPTO Updates Guidance For More Flexible Examination Of Design Patent Applications Related To Computer-Generated Interfaces And Icons
Article
23 Mar 2026
Antibody-Drug Conjugates
Article
19 Mar 2026
Federal Circuit Refuses To Construe "Configured For" As More Than "Capable Of"
Article
19 Mar 2026
The Doctrine Of Inherency In The Context Of An Obviousness Analysis
Article
17 Mar 2026
REGENXBIO, Inc. v. Sarepta Therapeutics: Recombinant DNA Molecule Patent-Eligibility Under 35 U.S.C. § 101
Article
19 Feb 2026
Deposit Of Biological Material Is Not Always Necessary To Satisfy The Enablement Requirement If The Biological Material Is Known And Readily Available At The Time The Patent Is Granted
Article
26 Dec 2025
Reversal Of An Obviousness-Inherency Position
Article
17 Dec 2025
USPTO Issues New Guidance And Updates The MPEP Following Ex Parte Desjardins
Article
04 Nov 2025
USPTO Announces Two New Pilot Programs To Expedite Prosecution
Article
08 Oct 2025
Ex Parte Desjardins Bolsters Patent Eligibility For AI-related Inventions As Appeals Review Panel Vacates Board's 101 Rejection
Article
05 Sep 2025
Different Mechanism Leads To Lack Of Reasonable Expectation Of Success
Article
07 Aug 2025
Appeal Of Examiner's Final Rejection Of Claims 18-20 Reversed By PTAB
